LDE225 in Combination With Paclitaxel in Patients With Advanced Solid Tumors - A Multicenter Phase I Trial
Phase of Trial: Phase I
Latest Information Update: 20 Mar 2017
Price : $35 *
At a glance
- Drugs Sonidegib (Primary) ; Paclitaxel
- Indications Anal cancer; Breast cancer; Cholangiocarcinoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Uterine cancer
- Focus Adverse reactions
- 20 Mar 2017 Results assessing safety and efficacy of sonidegib in combination with paclitaxel, published in the Investigational New Drugs
- 23 Nov 2016 Status changed from active, no longer recruiting to completed.
- 28 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.